[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367454-105":59,"doc-detail-367454-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-cold-immunological-landscape-of-atm-deficient-cancers","The cold immunological landscape of ATM-deficient cancers","","ATM gene loss is studied for its impact on tumor immunogenicity, an area that remains poorly defined despite known links between DNA repair defects and increased tumor immune recognition. Isogenic ATM-null models were generated in murine breast and colorectal cancer cell lines and validated by PCR and western blot. Tumor immune infiltration was quantified by flow cytometry and immunohistochemistry, while tumor growth and anti-PD-1 response were assessed in vivo. Effects of DNA-damaging agents on interferon-stimulated gene signaling were compared, showing that etoposide most strongly activated type I interferon pathways yet checkpoint blockade failed to enhance efficacy or reshape the microenvironment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-cold-immunological-landscape-of-atm-deficient-cancers/367454/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-cold-immunological-landscape-of-atm-deficient-cancers/367454.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is known about DNA repair gene mutations and tumor immunogenicity, and what is the gap for ATM?","Question",{"text":112,"@type":113},"Many DNA repair defects can increase tumor immunogenicity and immune infiltration, but the consequences of ATM loss on immunogenicity are poorly understood.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were ATM-null cancer models generated and validated in this study?",{"text":117,"@type":113},"Isogenic ATM-null models were created using CRISPR in murine triple-negative breast (4T1) and colorectal (CT26) cell lines, with ATM inactivation confirmed by PCR and western blot.",{"name":119,"@type":110,"acceptedAnswer":120},"What was the key finding about immune checkpoint blockade and type I interferon signaling in ATM-null tumors?",{"text":121,"@type":113},"Although etoposide strongly activated type I interferon and ISG expression, PD-1-targeted immune checkpoint blockade did not improve therapeutic activity or modify the tumor microenvironment, suggesting type I IFN signaling alone was insufficient in immunologically cold ATM-null neoplasms.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367454,1790513590,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Open access Original research  \nThe cold immunological landscape of ATM-deficient cancers  \nSonali Sinha,1 Victor Ng,1 Ardijana Novaj,1 Yingjei Zhu,2 Shu Yazaki,1 Xin Pei,1 Fatemeh Derakhshan,3 Fresia Pareja,2 Jeremy Setton,1 Flavie Naulin,4 Manuel Beltrán-Visiedo,4 Ethan Shin,1 Ana Leda F Longhini,5 Rui Gardner,5 Jennifer Ma,1 Kevin Ma,1 Anne Roulston,6 Stephen Morris,6 Maria Koehler,7 Simon Powell,1 Ezra Rosen,8 Lorenzo Galluzzi,4 Jorge Reis-Filho,2 Atif Khan,1 Nadeem Riaz  1  \nTo cite: Sinha S, Ng V,  \nNovaj A, et al. The cold immunological landscape of ATM-deficient cancers. Journal for ImmunoTherapy of Cancer 2025;13:e010548 . doi:10 . 1136/ jitc-2024-010548  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-010548](jitc-2024-010548)) .  \nSS and VN contributed equally. Accepted 01 April 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Nadeem Riaz; [riazn@mskcc.org](riazn@mskcc.org)  \nAtif Khan; [khana7@mskcc.org](khana7@mskcc.org)  \nABSTRACT  \nBackground Mutations in genes encoding DNA repair factors, which facilitate mismatch repair, homologous recombination, or DNA polymerase functions, are known to enhance tumor immunogenicity. Ataxia telangiectasia mutated (ATM) is a central regulator of DNA double-strand break repair and is frequently affected by somatic or germline mutations in various cancer types, including breast, prostate, pancreatic, and lung cancer. However, the consequences of ATM loss on tumor immunogenicity are poorly understood.  \nMethods We generated isogenic ATM-null models using CRISPR in murine triple-negative breast (4T1) and colorectal (CT26) cancer cell lines. ATM inactivation was confirmed by PCR and western blot. Immune  \ncell infiltrates were assessed by flow cytometry and immunohistochemistry in both murine tumors and human samples from breast and lung cancers (via The Cancer Genome Atlas and institutional cohorts) . In vivo, the impact of ATM loss on tumor growth and response to immune checkpoint blockade (anti-programmed cell death protein-1 (PD-1)) was evaluated. Furthermore, we compared the effects of different DNA-damaging agents—including an ATR inhibitor (RP-3500), a PARP inhibitor (olaparib), and the topoisomerase II inhibitor etoposide—on interferon-stimulated gene (ISG) expression and immune modulation.  \nResults We find that—in contrast to other DNA repair defects—ATM deficiency (1) fails to encourage immune effector cell infiltration into tumors, and (2) does not enable immune cell recruitment via synthetic lethality strategies in clinical trials, such as with ATR inhibition. Assessing various DNA-damaging agents in Atm null tumors revealed a differential activation of type I interferon (IFN) signaling, with etoposide, a topoisomerase II inhibitor, emerging asthe strongest activator of ISG under these conditions. Yet, PD-1-targeted immune checkpoint blockade does not bolster the therapeutic activity of etoposide in Atm-null syngeneic tumor models, nor does it modify the tumor microenvironment, suggesting that type I IFN signaling alone is insufficient to overcome immunosuppression in immunologically cold ATM null neoplasms.  \nConclusions ATM deficiency, while compromising  \nDNA repair and enhancing sensitivity to radiation and ATR inhibition, does not increase tumor antigenicity or immunogenicity. Altogether, our results have important  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Genetic mutations in many DNA repair genes enhance tumor immunogenicity; however, whether mutations in ataxia telangiectasia mutated (ATM) influence tumor immunogenicity is unknown.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ This study finds that ATM-mutated tumors have a distinct behavior from","cbCaisYhJgZgQ4ly","https://ap.wps.com/l/cbCaisYhJgZgQ4ly","pdf",2418951,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy\n# Introduction","[{\"question\":\"What is known about DNA repair gene mutations and tumor immunogenicity, and what is the gap for ATM?\",\"answer\":\"Many DNA repair defects can increase tumor immunogenicity and immune infiltration, but the consequences of ATM loss on immunogenicity are poorly understood.\"},{\"question\":\"How were ATM-null cancer models generated and validated in this study?\",\"answer\":\"Isogenic ATM-null models were created using CRISPR in murine triple-negative breast (4T1) and colorectal (CT26) cell lines, with ATM inactivation confirmed by PCR and western blot.\"},{\"question\":\"What was the key finding about immune checkpoint blockade and type I interferon signaling in ATM-null tumors?\",\"answer\":\"Although etoposide strongly activated type I interferon and ISG expression, PD-1-targeted immune checkpoint blockade did not improve therapeutic activity or modify the tumor microenvironment, suggesting type I IFN signaling alone was insufficient in immunologically cold ATM-null neoplasms.\"}]","The cold immunological landscape of ATM-deficient cancers | PDF",1790170853,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e595e676cb5b381af77118cb0a115382.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d406a4fcaff6bc5bca2c4fb48d3149e0.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/482e8601673ef3ea7e3f884a8b31b918.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8541ec307beabdf882d34a4af0e51c72.webp",980,1306]